Abstract
Background: Radix Wikstroemia indica is a traditional Chinese medicine (TCM) used as antiinflammatory and anti-tumor drug. However, it has serious hepatotoxicity, "Sweat soaking method" processed could effectively decrease its hepatotoxicity.
Objective: The objective of this study is to study the effects of Radix Wikstroemia indica on six kinds of cytochrome P450(CYP450) isozymes of rat liver microsomes before and after processing, and to study the mechanism of Radix Wikstroemia indica processed by the "Sweat soaking method" to reduce liver toxicity in rats.
Methods: In this study, the effects of Radix Wikstroemia indica and processed Radix Wikstroemia indica on the six main CYP450 isoforms (2E1, 1A2, 2C6, 2D1, 2C11, and 3A1) were investigated in vitro. Using a cocktail probe of CYP450 isoform-specific substrates and their metabolites, we carried out in vitro enzymatic studies in liver microsomal incubation systems via UPLC-MS/MS.
Results: The results showed that the established UPLC-MS/MS method was precise and reliable. Compared with the blank group, the activities of six enzymes in the RWI and PRWI groups were higher than those in the blank group. At the same dose, the enzyme activities of CYP2E1, CYP1A2, CYP2C6, CYP2C11, and CYP3A1 increased with the increase in dose, and the enzyme activities of the RWI group were higher than those of the PRWI group. The enzyme activities of CYP2E1 and CYP1A2 in the Radix Wikstroemia indica group were significantly increased compared with the blank group, CYP3A1 in the RWI high-dose group was higher than that in the blank group and PRWI group with statistical differences (p < 0.05 or p < 0.01).
Conclusion: The processed Radix Wikstroemia indica could reduce liver injury, and its detoxication mechanism might be related to the decrease in enzyme activity of CYP1A2, CYP2E1 and CYP3A1.
Graphical Abstract
[http://dx.doi.org/10.1042/bj2950321] [PMID: 8216237]
[http://dx.doi.org/10.1016/j.phymed.2018.03.063] [PMID: 29691116]
[PMID: 28124606]
[http://dx.doi.org/10.1007/s00204-020-02936-7] [PMID: 33111191]
[http://dx.doi.org/10.1016/j.jep.2015.08.035] [PMID: 26318744]
[http://dx.doi.org/10.1016/0165-6147(90)90245-4] [PMID: 2200179]
[PMID: 28936835]
[http://dx.doi.org/10.1007/s00216-014-7915-4] [PMID: 24894520]
[http://dx.doi.org/10.1016/j.pharmthera.2012.12.007] [PMID: 23333322]
[http://dx.doi.org/10.1124/dmd.112.046094] [PMID: 23043184]
[http://dx.doi.org/10.1016/j.freeradbiomed.2020.06.030] [PMID: 32738395]
[http://dx.doi.org/10.1155/2020/4875764] [PMID: 33014105]
[http://dx.doi.org/10.1111/bcpt.13313] [PMID: 31468699]
[http://dx.doi.org/10.7150/ijms.38527] [PMID: 32132876]
[http://dx.doi.org/10.1016/j.intimp.2019.05.010] [PMID: 31302451]
[http://dx.doi.org/10.3892/ijmm.2016.2461] [PMID: 26797017]
[http://dx.doi.org/10.3389/fphar.2010.00129] [PMID: 21918647]
[http://dx.doi.org/10.2174/1389200221999210101233135] [PMID: 33397254]
[http://dx.doi.org/10.1177/0960327120937047] [PMID: 32633153]
[http://dx.doi.org/10.1021/acs.molpharmaceut.7b00957] [PMID: 29232137]
[http://dx.doi.org/10.1146/annurev.pharmtox.39.1.1] [PMID: 10331074]
[http://dx.doi.org/10.1021/tx4004159] [PMID: 24308637]